BACKGROUND: Conventional plasmids for gene therapy produce low-level and short-term gene expression. In this study, we develop a novel nonviral vector that robustly and persistently expresses the hypoxia-inducible factor-1 alpha (HIF-1alpha) therapeutic gene in the heart, leading to functional benefits after myocardial infarction. METHODS AND RESULTS: We first created minicircles (MC) carrying double-fusion reporter gene consisting of firefly luciferase and enhanced green fluorescent protein (Fluc-eGFP) for noninvasive measurement of transfection efficiency. Mouse C2C12 myoblasts and normal FVB/N mice were used for in vitro and in vivo confirmation, respectively. Bioluminescence imaging showed stable MC gene expression in the heart for >12 weeks and the activity level was 5.6+/-1.2-fold stronger than regular plasmid at day 4 (P<0.01). Next, we created MC carrying HIF-1alpha (MC-HIF-1alpha) therapeutic gene for treatment of myocardial infarction. Adult FVB/N mice underwent left anterior descending ligation and were injected intramyocardially with: (1) MC-HIF-1alpha; (2) regular plasmid carrying HIF-1alpha (PL-HIF-1alpha) as positive control; and (3) PBS as negative control (n=10/group). Echocardiographic study showed a significantly greater improvement of left ventricular ejection fraction in the MC group (51.3%+/-3.6%) compared to regular plasmid group (42.3%+/-4.1%) and saline group (30.5%+/-2.8%) at week 4 (P<0.05 for both). Histology demonstrated increased neoangiogenesis in both treatment groups. Finally, Western blot showed MC express >50% higher HIF-1alpha level than regular plasmid. CONCLUSIONS: Taken together, this is the first study to our knowledge to demonstrate that MC can significantly improve transfection efficiency, duration of transgene expression, and cardiac contractility. Given the serious drawbacks associated with most viral vectors, we believe this novel nonviral vector can be of great value for cardiac gene therapy protocols.
BACKGROUND: Conventional plasmids for gene therapy produce low-level and short-term gene expression. In this study, we develop a novel nonviral vector that robustly and persistently expresses the hypoxia-inducible factor-1 alpha (HIF-1alpha) therapeutic gene in the heart, leading to functional benefits after myocardial infarction. METHODS AND RESULTS: We first created minicircles (MC) carrying double-fusion reporter gene consisting of firefly luciferase and enhanced green fluorescent protein (Fluc-eGFP) for noninvasive measurement of transfection efficiency. MouseC2C12 myoblasts and normal FVB/N mice were used for in vitro and in vivo confirmation, respectively. Bioluminescence imaging showed stable MC gene expression in the heart for >12 weeks and the activity level was 5.6+/-1.2-fold stronger than regular plasmid at day 4 (P<0.01). Next, we created MC carrying HIF-1alpha (MC-HIF-1alpha) therapeutic gene for treatment of myocardial infarction. Adult FVB/N mice underwent left anterior descending ligation and were injected intramyocardially with: (1) MC-HIF-1alpha; (2) regular plasmid carrying HIF-1alpha (PL-HIF-1alpha) as positive control; and (3) PBS as negative control (n=10/group). Echocardiographic study showed a significantly greater improvement of left ventricular ejection fraction in the MC group (51.3%+/-3.6%) compared to regular plasmid group (42.3%+/-4.1%) and saline group (30.5%+/-2.8%) at week 4 (P<0.05 for both). Histology demonstrated increased neoangiogenesis in both treatment groups. Finally, Western blot showed MC express >50% higher HIF-1alpha level than regular plasmid. CONCLUSIONS: Taken together, this is the first study to our knowledge to demonstrate that MC can significantly improve transfection efficiency, duration of transgene expression, and cardiac contractility. Given the serious drawbacks associated with most viral vectors, we believe this novel nonviral vector can be of great value for cardiac gene therapy protocols.
Authors: Mei Huang; Denise A Chan; Fangjun Jia; Xiaoyan Xie; Zongjin Li; Grant Hoyt; Robert C Robbins; Xiaoyuan Chen; Amato J Giaccia; Joseph C Wu Journal: Circulation Date: 2008-09-30 Impact factor: 29.690
Authors: Joseph C Wu; Ian Y Chen; Yanling Wang; Jeffrey R Tseng; Ankush Chhabra; Mahdi Salek; Jung-Joon Min; Michael C Fishbein; Ronald Crystal; Sanjiv S Gambhir Journal: Circulation Date: 2004-08-10 Impact factor: 29.690
Authors: Neal S Kleiman; Nirav C Patel; Keith B Allen; Michael Simons; Seppo Ylä-Herttuala; Elaine Griffin; Victor J Dzau Journal: Am J Cardiol Date: 2003-11-07 Impact factor: 2.778
Authors: Jeong Hyun; Monica Grova; Hossein Nejadnik; David Lo; Shane Morrison; Daniel Montoro; Michael Chung; Andrew Zimmermann; Graham G Walmsley; Min Lee; Heike Daldrup-Link; Derrick C Wan; Michael T Longaker Journal: Stem Cells Transl Med Date: 2013-08-09 Impact factor: 6.940
Authors: Matti Adam; Nigel Geoffrey Kooreman; Ann Jagger; Markus U Wagenhäuser; Dennis Mehrkens; Yongming Wang; Yosuke Kayama; Kensuke Toyama; Uwe Raaz; Isabel N Schellinger; Lars Maegdefessel; Joshua M Spin; Jaap F Hamming; Paul H A Quax; Stephan Baldus; Joseph C Wu; Philip S Tsao Journal: Arterioscler Thromb Vasc Biol Date: 2018-08 Impact factor: 8.311
Authors: Maarten A Lijkwan; Alwine A Hellingman; Ernst J Bos; Koen E A van der Bogt; Mei Huang; Nigel G Kooreman; Margreet R de Vries; Hendrika A B Peters; Robert C Robbins; Jaap F Hamming; Paul H A Quax; Joseph C Wu Journal: Hum Gene Ther Date: 2014-01-07 Impact factor: 5.695
Authors: Sadia Mohsin; Mohsin Khan; Haruhiro Toko; Brandi Bailey; Christopher T Cottage; Kathleen Wallach; Divya Nag; Andrew Lee; Sailay Siddiqi; Feng Lan; Kimberlee M Fischer; Natalie Gude; Pearl Quijada; Daniele Avitabile; Silvia Truffa; Brett Collins; Walter Dembitsky; Joseph C Wu; Mark A Sussman Journal: J Am Coll Cardiol Date: 2012-07-26 Impact factor: 24.094